Kijima Toshiki

キジマトシキ | Kijima Toshiki

Affiliation and department：
Job title：講師

Research field (1)： Urology

Research keywords (5)： Heat shock proteins , immunotherapy , Renal cell carcinoma , Urothelial cancer , Prostate cancer

Research theme for competitive and other funds (4)：

2022 - 2025 CHAperone-Mediated Protein degradation (CHAMP) based novel therapy for castration resistant prostate cancer
2018 - 2020 Novel therapy targeting androgen receptor splice variants by inhibiting heat shock factor 1 (HSF1) for the treatment of castration-resistant prostate cancer
2014 - 2015 ビスホスホネートによるSTAT1抑制機構および泌尿器癌治療増感作用の解析
2011 - 2012 Sensitizing effects of bisphosphonate to radiotherapy and chemotherapy in urologic cancers.

Papers (120)：

Daisuke Mamiya, Toshiki Kijima, Atsuko Takada-Owada, Hidetoshi Kokubun, Toshitaka Uematsu, Kohei Takei, Tsunehito Kambara, Kazuyuki Ishida, Hiroshi Taneichi, Takao Kamai. A patient with oligometastatic hormone-sensitive prostate cancer who achieved long-term progression-free survival following cytoreductive radical prostatectomy and metastasectomy. IJU case reports. 2024. 7. 2. 165-168
Mariko Kotono, Toshiki Kijima, Atsuko Takada-Owada, Naoya Okubo, Ryo Kurashina, Hidetoshi Kokubun, Toshitaka Uematsu, Kohei Takei, Kazuyuki Ishida, Takao Kamai. Increased expression of ATP-binding cassette transporters in enfortumab vedotin-resistant urothelial cancer. IJU case reports. 2024. 7. 2. 173-176
Hidetoshi Kokubun, Toshiki Kijima, Atsuko Takada-Owada, Daisuke Mamiya, Ryo Kurashina, Naoya Okubo, Toshitaka Uematsu, Kohei Takei, Kazuyuki Ishida, Takao Kamai. A case of adrenal undifferentiated pleomorphic sarcoma with tertiary lymphoid structures responded to pembrolizumab. IJU case reports. 2023. 6. 6. 440-444
Hiroki Shimoda, Toshiki Kijima, Atsuko Takada-Owada, Kazuyuki Ishida, Takao Kamai. A case of perirenal extra-adrenal myelolipoma mimicking liposarcoma. Urology case reports. 2023. 50. 102523-102523
Toshiki Kijima, Shohei Fukuda, Hiroshi Fukushima, Sho Uehara, Yosuke Yasuda, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Kazutaka Saito, Yasuhisa Fujii. The role of multimodal salvage therapy in the management of recurrent adrenocortical carcinoma. Japanese journal of clinical oncology. 2023. 53. 5. 436-442

ｍore...

MISC (39)：

国分英利, 安士正裕, 今里直樹, 下田海生, 中村岳, 武井航平, 鈴木一生, 西原大策, 木島敏樹, 石田和之, et al. Time-frame analysis of biochemical recurrence after robot-assisted radical prostatectomy for high-risk prostate cancer. 日本泌尿器科学会総会(Web). 2023. 110th
鈴木一生, 木島敏樹, 中村岳, 植松稔貴, 坂本和優, 西原大策, 別納弘法, 安士正裕, 釜井隆男, 大和田温子, et al. アベルマブ+アキシチニブ併用療法が奏効した下大静脈内腫瘍栓を伴う淡明細胞型腎細胞癌の1例. Kitakanto Medical Journal. 2022. 72. 1
鈴木一生, 木島敏樹, 今里直樹, 下田海生, 国分英利, 中村岳, 植松稔貴, 武井航平, 大和田温子, 西原大策, et al. アベルマブ+アキシチニブ併用療法により下大静脈内腫瘍栓のレベルダウンが得られた淡明細胞型腎細胞癌の2例. 日本泌尿器科学会東部総会プログラム・抄録集. 2022. 87th
鈴木一生, 木島敏樹, 岡崎明仁, 渕澤寛崇, 横山愛, 中村岳, 植松稔貴, 坂本和優, 大和田温子, 西原大策, et al. アベルマブ+アキシチニブ併用療法により下大静脈内腫瘍栓のレベルダウンが得られた淡明細胞型腎細胞癌の1例. 日本泌尿器科学会東部総会プログラム・抄録集. 2021. 86th
渕澤寛崇, 木島敏樹, 岡崎明仁, 横山愛, 坂本和優, 鈴木一生, 西原大策, 別納弘法, 深堀能立, 安士正裕, et al. ニボルマブ+イピリムマブ併用療法が奏効した腎粘液管状紡錘細胞癌(Mucinous tubular and spindle cell carcinoma)の一例. 日本泌尿器科学会東部総会プログラム・抄録集. 2021. 86th

ｍore...

Education (2)：

2006 - 2012 Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences
1996 - 2002 Tokyo Medical and Dental University Faculty of Medicine School of Medicine

Work history (7)：

2020/01 - 現在 Dokkyo Medical University Urology Assistant professor
2016/03 - 2019/12 Tokyo Medical and Dental University Urology Assistant professor
2014/03 - 2016/02 National Institutes of Health National Cancer Institute Postdoctoral fellow
2008/10 - 2014/02 Tokyo Medical and Dental University Urology Assistant professor
2006/07 - 2008/09 Cancer Institute Hospital Urology Resident

Show all

Awards (2)：

2019/10 - Japan Society of Urologic Oncology Best poster award
2018/04 - Japanese Urological Association Best poster award

Association Membership(s) (1)：

Japanese Urological Association

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page